Clinical Research Directory

Inclusion Criteria: 1. Radiographically(CT, MRI or PET-CT, etc.) and histologically confirmed diagnosis of localized HER-2 expressing upper urothelial carcinoma( (cT1-4N0-2M0, HER-2 immunohistochemistry (IHC) ≥ 1+); high risk disease (according to EAU Guidelines for UTUC); planning to receive radical nephroureterectomy (RNU), distal ureterectomy (DU) or ureteroscopic ablation (UA). 2. Male or female aged 18 years and above; 3. Expected survival time greater than 12 weeks; 4. An ECOG status score of 0-2; 5. Agree to provide specimens of blood, urine, and tissue examination (for detection of MRD, PD-L1 expression, HER2 expression, tumor mutation load, immunohistochemistry, DNA and RNA detection, etc.); 6. The level of organ function must meet the following requirements: * hematological indicators: absolute neutrophil count ≥ 1.5 × 10\^9/L, platelet count ≥ 80 × 10\^9/L, hemoglobin ≥ 6.0 g/dL (can be maintained by symptomatic treatment) * hepatic function: total bilirubin ≤ 1.5 times the upper limit of normal, and glutathione and glutamic oxalacetic transaminase ≤ 2.5 times the upper limit of normal; * renal function: GFR ≥ 15 ml/min; * Subjects voluntarily joined the study, signed an informed consent form, were compliant, and cooperated with the follow-up. Exclusion Criteria: 1. Live attenuated vaccines, other than COVID-19 vaccine, received within 4 weeks prior to treatment or scheduled to be received during the study period 2. Active, known or suspected autoimmune disease; 3. Known history of primary immunodeficiency; 4. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation 5. Female patients who are pregnant or breastfeeding 6. Untreated acute or chronic active hepatitis B or C infection. Patients who are receiving antiviral therapy with monitoring of viral copy number and are eligible for enrollment as determined by the physician on an individual patient basis; 7. Previous use of immunosuppressive drugs, excluding nasal spray and inhaled corticosteroids or physiologic doses of systemic steroids (i.e., no more than 10 mg/day prednisolone or equivalent pharmacologic physiologic doses of other corticosteroids), within 4 weeks prior to initiation of therapy 8. Known or suspected allergy history to tislelizumab and disitamab vedotin. 9. With a clear history of active tuberculosis. 10. Prior PD-1/PD-L1/CTLA-4 antibody or other immunotherapy; 11. Those who are participating in other clinical studies 12. Men of reproductive potential or women with the potential to become pregnant who are not using reliable contraception 13. Uncontrolled co-morbidities, including but not limited to * HIV-infected individuals (HIV-positive); * Severe infections that are active or poorly controlled clinically (including patients in the period of neocoronavirus infection) * Evidence of the presence of severe or uncontrolled systemic disease (e.g., severe psychiatric, neurological disease, epilepsy or dementia, unstable or uncompensated respiratory, cardiovascular, hepatic or renal disease, uncontrolled hypertension \[i.e., defined as greater than or equal to CTCAE grade 2 hypertension despite medication\]).